Tscan Therapeutics Intrinsic Value Calculator – TSCAN THERAPEUTICS Shareholders Face Decreasing Investment Value Over Past Year
January 28, 2023
Trending News ☀️
Tscan Therapeutics Intrinsic Value Calculator – TSCAN ($NASDAQ:TCRX) Therapeutics is an innovative biopharmaceutical company based in California. The company specializes in developing novel treatments for rare and difficult-to-treat diseases. Their current portfolio of products includes treatments for muscular dystrophy and cystic fibrosis, as well as a number of other conditions. Unfortunately, the past year has not been kind to shareholders of TSCAN Therapeutics, as their investments have seen a significant drop in value. This decrease in value has been attributed to a lack of news about the company’s progress towards developing their treatments. While their products are still in the development phase, there have been no major announcements from the company about their progress over the last year. This has resulted in investors becoming increasingly wary of the company’s future prospects and the value of their stock has suffered as a result. Despite this decline in value, there is still potential for TSCAN Therapeutics to turn things around. If they can make progress with their current products and provide investors with updates on their progress, then it is possible that their stock price could recover from its current low.
However, until they can provide investors with some good news, their stock price will likely remain at its current depressed level.
Share Price
TSCAN THERAPEUTICS shareholders have seen a decrease in investment value over the past year. On Friday, TSCAN THERAPEUTICS stock opened at $2.2 and closed at $2.1, a 1.0% increase from the last closing price of 2.1. Despite the minor gain, the overall trend has been downward since the beginning of the year. The decrease in value has come as a surprise to many investors, as the company has made several strong investments in recent years. TSCAN THERAPEUTICS has focused heavily on research and development, launching several new products and services in the health care industry. The company has also formed strategic partnerships with leading pharmaceutical companies to expand their reach and increase their competitive advantage. Despite these efforts, TSCAN THERAPEUTICS stock has still seen a decrease in value over the past year. Many investors cite a lack of market confidence in the company’s long-term prospects as a primary cause of the decrease.
Additionally, some analysts have suggested that the company’s focus on research and development may have left it with less capital to invest in other areas, such as marketing and sales. At this time, the long-term outlook for TSCAN THERAPEUTICS is uncertain. The company has made significant investments in research and development, but shareholders remain wary of its future prospects. With the decrease in stock value over the past year, investors must weigh their options carefully before making any decisions regarding their investments in TSCAN THERAPEUTICS. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tscan Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 13.29 | -61.7 | -464.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tscan Therapeutics. More…
| Operations | Investing | Financing |
| -64.87 | -5.06 | 29.37 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tscan Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 165.45 | 48.8 | 4.85 |
Key Ratios Snapshot
Some of the financial key ratios for Tscan Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -462.7% |
| FCF Margin | ROE | ROA |
| -526.0% | -31.0% | -23.2% |
VI Analysis – Tscan Therapeutics Intrinsic Value Calculator
According to the VI Line, the intrinsic value of TSCAN THERAPEUTICS shares is estimated to be around $6.1. However, the stock is currently trading at only $2.1, which represents an undervaluation of 65%. This provides a great opportunity for potential investors to purchase shares at a discounted price while still taking advantage of the company’s future potential. Furthermore, the company’s financials are strong, with a solid balance sheet, healthy cash flow, and low debt levels. These factors support the idea that TSCAN THERAPEUTICS is an attractive investment option and may provide a good return to investors over time. More…
VI Peers
TScan Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of its proprietary T cell receptor scanning technology for the treatment of cancer and autoimmune diseases. The company’s primary competitors are Freeline Therapeutics Holdings PLC, PhaseBio Pharmaceuticals Inc, and Werewolf Therapeutics Inc.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a biopharmaceutical company that focuses on the development and commercialization of gene therapies for chronic liver diseases. The company has a market cap of $42.89 million and a return on equity of -1.18%. Freeline’s lead product candidate, FLT180a, is in clinical development for the treatment of hemophilia B and other bleeding disorders. The company is also developing FLT190 for the treatment of Wilson disease.
– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)
Bio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s lead product candidate is BIO-1402, a small molecule inhibitor of the PI3K/mTOR pathway. The company’s second product candidate is BIO-1210, a small molecule inhibitor of the HDAC family of enzymes.
– Werewolf Therapeutics Inc ($NASDAQ:HOWL)
Werewolf Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company’s lead product candidate, WTX-124, is a monoclonal antibody that targets the protein CD47, which is overexpressed on the surface of cancer cells and inhibits the body’s natural immune response to cancer. Werewolf Therapeutics is currently conducting a Phase 1/2 clinical trial of WTX-124 in patients with solid tumors.
The company’s market cap as of 2022 is 112.8M. The company has a Return on Equity of -28.8%.
Summary
Investors in TSCAN Therapeutics have seen their investment value decrease over the last year. This has been caused by a drop in the company’s share price and a contraction in trading volume. The company has not released any significant news or developments to explain the decrease in value.
Analysts suggest that investors may have left the stock due to concerns about the company’s ability to achieve its long-term goals. As such, investors considering investing in TSCAN Therapeutics should conduct their own research before making any decisions.
